purpose study evaluate effect age sex race comorbid medical condition asc yield proliferation vitro osteogenic potential transduce nontransduced cell order better characterize full clinical potential human ascs cellbased gene therapy application bone repair hypothesize increase age presence medical comorbidities would negatively affect cell yield proliferation well osteogenic potential transduce ascs institutional review board approval obtain prior collection human tissue human adipose tissue collect sterile fashion infrapatellar fat pad patient undergo primary total knee arthroplasty tka osteoarthritis institution fat pad partially excise discard typical tka age sex raceethnicity medical comorbidities record deidentified sample comorbid patient define medically treat metabolic inflammatory disease include diabetes mellitus rheumatoid arthritis coronary artery disease patient receive immunosuppressive medication active smoker also consider comorbid exclusion criterion include patient greater 80 year old congenital disorder bone cartilage osteonecrosis active infection history infection operative knee revision tka collect adipose tissue process use previously publish protocol obtain stromal vascular fraction svf 13 37. briefly adipose sample extensively wash dulbecco 's pb dpbs lonza basel ch remove debris red blood cell tissue mechanically digest scissor enzymatically digest 0.1 collagenase sigmaaldrich st. louis mo 37 ¡ãc 90 min solution filter wash three time dpbs result svf resuspend dulbecco 's modify eagle medium dmem corn corn ny contain 10 fetal bovine serum gibco amarillo tx antibiotic mix contain 100 unitml penicillin 100 ¦Ìgml streptomycin 250 ngml amphotericin b lonza basel ch isolate svf cell count tc20 automate cell counter biorad hercules ca use trypan blue plat expansion concentration 23 ¡Á 106 cell per 10 cm dish cell maintain 37 ¡ãc 5 co. culture medium replace every 34 day cell passaged weekly adherent cell trypsinized replated density 0.71.0 ¡Á 106 cell per 10 cm dish donor analyze initial cell yield growth characteristic determine cell number successive passage passage 3 ascs subset 44 donor 21 healthy 23 comorbid undergo immunophenotypic analysis transduction lv vector system express bmp2 subsequent vitro analysis osteogenic potential detail 44 donor reach threshold number cell passage 3 require order perform vitro analysis asc cellsurface marker expression characterize use multicolor flow cytometric facs analysis cd marker panel base criterion describe mesenchymal tissue stem cell committee international society cellular therapy isct 38. trypsinization cell wash resuspend bd pharmingen stain buffer bd bioscience franklin lake nj aliquot suspension 150 ¦Ìl use cell count trypan blue count remain solution resuspend concentration 5 ¡Á 10 cellsml aliquot suspension 100 ¦Ìl transfer 1.5 ml eppendorf tube stain follow antibody cd44 cd73 cd90 hmsc negative cocktail cd34 cd11b cd19 hladr unstained singlecolor control also prepare tube incubate ice dark 30 min cell wash twice resuspend 200 ¦Ìl pharmingen stain buffer prepare dapi work concentration 1 ¦Ìgml analysis perform use bd facsaria iii bd bioscience compensation set singlecolor control unstained cell forwardscatter sidescatter use exclude debris doublet data analyze use flowjo software flowjo llc ashland ascs transduce twostep transcriptional amplification tsta vector system describe previously publish protocol 39,40,41. briefly tsta system us two lv vector gal4vp16 transactivator vector lvrhmlvgal4vp16 transgene expression vector encode bmp2 lvg5bmp2 lentiviral vector generate transfecting 293 cell american type culture collection manassas va describe previous protocol 40 42. determine functional titer lv vector ht29 cell atcc manassas va transduce dilute vector prep genomic dna extract 3 day transduction lentiviral vector copy human cell number genomic dna quantify qx200 droplet digital pcr system biorad herclus ca use hiv1 psi region human syndecan4 sdc4 primer probe lv titer calculate vector copy number per cell reach passage 3 ascs plat density 1 ¡Á 106 cellsdish next day cell transduce viral vector multiplicity infection 33 presence 8 ¦Ìgml polybrene cell incubate overnight next day medium aspirate replace remove extracellular virus bmp2 production transduce cell evaluate two 10 cm dish 1 ¡Á 106 transduce cell overnight transduction describe cell wash resuspend fresh medium cell maintain culture regular medium change bmp2 production 24 h period assess collect supernatant 2 7 14days posttransduction bmp2 quantify commercial bmp2 elisa kit quantikine rd system minneapolis mn sample run duplicate average across two plate use donor bmp2 production standardize cell number report nanogram bmp2 per 1 ¡Á 106 cell per 24 h. population double time pdt determine base growth data p2 p3 cell number p2 p3 well number day p2 p3 record pdt determine use double timeexponential growth equation t2t1 time day p2 p3 q2q1 represent cell number p3 p2 respectively 43. osteogenic differentiation profile nontransduced lvtstabmp2 transduce ascs assess use alizarin red ar stain quantification spectrophotometry 23 44 2 ¡Á 105 nontransduced transduce cell plat duplicate sixwell plate maintain osteogenic medium 14 day prior ar stain osteogenic induction medium include dmem 10 fbs antibioticsantimycotic along 10 ¦Ìm dexamethasone 50 ¦Ìgml lascorbic acid 10 mm betaglycerophosphate 14 day cell fix 10 formaldehyde 10 min wash pb stain 2 alizarin red solution 30 min room temperature remain dye remove distil water ar stain image use echo revolve microscope model rvl100b2 bico boston store 20 ¡ãc prior quantification quantification alizarin red colorimetric assay use 800 ¦Ìl 10 acetic acid add stain cell well sixwell plate incubate room temperature 30 min gentle shake cell scrap transfer 1.5 ml eppendorf tube subsequently incubate 85 ¡ãc 10 min centrifugation 20,000 g 5 min 500 ¦Ìl supernatant transfer new tube supernatant neutralize 10 ammonium hydroxide 150 ¦Ìl aliquot sample add triplicate opaquewalled clearbottom 96well plate absorbance read 405 nm plate reader model 680 biorad hercules ca usa stemness harvest ascs define selfrenewal capacity assess quantification colony form unitfibroblast cfuf assay nontransduced lvtstabmp2 transduce ascs 24 h transduction 48 h plat nontransduced cell cell trypsinized filter 70 ¦Ìm strainer remove cell clump count use automate cell counter trypan blue cell seed triplicate density 100 200 cell per 10 cm plate cell maintain culture standard growth medium 14 day medium change every 34 day 14 day culture cell wash stain crystal violet colony manually enumerate three different reader kc mcg o replicate average reader data present condition mean three reader average interrater reliability assess intraclass correlation coefficient icc twoway mix effect model characterize excellent ¡Ý0.9 good 0.750.9 fair 0.40.75 poor 0.4 45 46. spss software ibm spss statistic window version 24.0. armonk ny ibm corp use analysis data significance level set 0.05. data present mean standard deviation assess normality shapirowilk test prior analysis cell number different passage p0p3 population double time pdt compare patient without comorbidities use mannwhitney u test result adjust age sex bmi race control confound factor use linear regression difference cell number pdt also evaluate male vs. female patient patient different race use mannwhitney u test evaluate bmp2 production mineralization potential selfrenewal capacity subset patient without comorbidities use independent sample ttest mannwhitney u test applicable result control age sex bmi race smoke prior arthroscopic knee surgery use linear regression chisquare test use univariate analysis different categorical variable pearson chisquare result fisher exact test result expect value 5 report applicable finally pearson correlation analysis perform determine relationship bmp2 level different study parameter age sex bmi cfuf well number cell per passage bmi